26 completed, 2 withdrawn, 1 terminated. 14 Not applicable, 10 Phase 3, 5 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 14 | Completed 12, Withdrawn 2 |
| Phase 3 | 10 | Completed 9, Terminated 1 |
| Phase 4 | 5 | Completed 5 |
Follow InQpharm Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Benefit and Tolerability of IQP-LU-104 in Weight Loss High dose IQP-LU-104 (5120mg), Low dose IQP-LU-104 (2560mg), Placebo - Overweight, Obesity | Not applicable | Completed | InQpharm Group | 108 | 2019-03-05 | 2022-08-03 |
| Vasoactive Effects of IQP-AS-118 in Healthy Individuals IQP-AS-118, Placebo - Blood Flow, Cardiovascular Disease | Not applicable | Withdrawn | InQpharm Group | 2018-03-01 | 2020-02-12 | |
| Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity Mouthrinse (IQP-OLP-101) - Dentin Sensitivity | Not applicable | Completed | InQpharm Group | 30 | 2017-08-25 | 2018-01-03 |
| Efficacy and Safety of Litramine in 1 Year Weight Loss Study Litramine, Placebo tablet - Obesity; Excess Calories, Overweight and Obesity | Not applicable | Completed | InQpharm Group | 166 | 2017-08-14 | 2020-02-28 |
| Benefit and Tolerability of IQP-AE-103 in Weight Loss IQP-AE-103 (330mg), IQP-AE-103 (165mg), Placebo - Overweight, Obesity | Not applicable | Completed | InQpharm Group | 108 | 2017-05-01 | 2018-01-03 |
| Benefit of IQP-AO-101 for Sleep IQP-AO-101, Placebo - Insomnia, Nonorganic | Not applicable | Completed | InQpharm Group | 50 | 2017-04-25 | 2018-01-03 |
| Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol IQP-AS-118, Placebo - Blood Pressure, Low Density Lipoprotein Cholesterol Level | Not applicable | Completed | InQpharm Group | 54 | 2017-03-17 | 2019-03-04 |
| Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness IQP-AS-121 - Fatigue | Not applicable | Withdrawn | InQpharm Group | 2016-11-01 | 2020-02-12 | |
| Efficacy of Glucosanol™ in Reducing Post-prandial Glucose Levels in Overweight Subjects Glucosanol 500mg, Placebo - Hyperglycemia, Postprandial | Not applicable | Completed | InQpharm Group | 24 | 2016-08-01 | 2017-02-08 |
| Influence of IQPAS-119 on Post-Marathon Susceptibility to Infections and Others IQP-AS-119, Placebo - Upper Respiratory Tract Symptoms | Not applicable | Completed | InQpharm Group | 75 | 2016-07-10 | 2018-01-03 |
| Efficacy and Safety of IQP-AK-102 in Reducing Appetite IQP-AK-102 - Appetite Regulation, Appetite Suppression | Not applicable | Completed | InQpharm Group | 36 | 2016-05-01 | 2018-01-03 |
| Efficacy and Safety of Glucosanol™ in Body Weight Reduction Glucosanol 350mg, Glucosanol 500mg, Placebo - Overweight and Obesity | Not applicable | Completed | InQpharm Group | 90 | 2016-05-01 | 2023-07-27 |
| Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects Dose 1 of IQP-VV-102, Dose 2 of IQP-VV-102, Placebo - Prediabetes, Hyperglycemia | Phase 3 | Completed | InQpharm Group | 27 | 2014-06-01 | 2015-11-10 |
| Safety and Efficacy of IQP-AK-102 in Reducing Appetite IQP-AK-102, Placebo - Weight Loss, Appetite Modulation (Focus of Study) | Phase 3 | Completed | InQpharm Group | 40 | 2014-01-01 | 2015-03-25 |
| Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea IQP-MM-101 - Diarrhoea | Not applicable | Completed | InQpharm Group | 101 | 2013-10-01 | 2020-03-04 |
| Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections IQP-AS-105, Placebo - Common Cold, Upper Respiratory Tract Infections | Phase 3 | Terminated | InQpharm Group | 140 | 2013-10-01 | 2016-02-12 |
| Safety and Efficacy of IQP- AK-102 in Reducing Body Weight IQP-AK-102, Placebo - Weight Loss | Phase 3 | Completed | InQpharm Group | 119 | 2013-07-01 | 2016-03-08 |
| IQP-PO-101 for the Regulation of Bowel Movement Frequency IQP-PO-101 - Constipation, Irregular Bowel Movement Frequency | Phase 3 | Completed | InQpharm Group | 50 | 2013-03-01 | 2014-01-14 |
| IQP-CL-101 in IBS Management IQP-CL-101, Placebo - Irritable Bowel Syndrome | Phase 3 | Completed | InQpharm Group | 100 | 2013-01-01 | 2015-03-26 |
| Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn IQP-LH-101 tablet, IQP-LH-101 liquid, Placebo - Postprandial Heartburn | Phase 4 | Completed | InQpharm Group | 41 | 2012-10-01 | 2013-03-11 |
Showing 20 of 29. Sign in to see all of them.
Overweight (10) · Obesity (9) · Weight Loss (8) · Hyperglycemia (2) · Body Weight (1) · Cardiovascular Diseases (1) · Common Cold (1) · Constipation (1) · Dentin Sensitivity (1) · Diarrhea (1) · Fatigue (1) · Hypersensitivity (1) · Irritable Bowel Syndrome (1) · Prediabetic State (1) · Respiratory Tract Infections (1)
Abortion, Induced (1) · IQP-CL-101 (1)
Germany (28)
Barbara Grube, MD (5) · Ralf Uebelhack (2) · Ralf Uebelhack, MD (2) · Ralf Uebelhack, MD, PhD (2) · Udo Bongartz, MD (2) · Minoo Lenarz, MD (1) · Ralf Uebelhack, MD, phD (1) · Ralf Uebelhack, PhD (1) · Ralf Uebelhack,, MD, PhD (1) · Regina Busch, MD (1) · Udo Bongartz (1) · Udo Bongartz, MD, PhD (1) · Udo Bongartz, PhD (1)
PMID 24006357, PMID 23505169, PMID 25067985, PMID 26074990, PMID 26435849, PMID 30863632, PMID 31186669, PMID 35130547, PMID 35571928, PMID 38830962